Výsledky vyhledávání

Autor: C. G. Haase, T. Uepping

Publikováno v: Klinische Neurophysiologie. 45:11-14

Die Therapie von Dystonien zielt auf die lokale Wirkung von Botulinumtoxinen (Btx) an der injizierten Muskulatur. In einigen Fallen wird dies jedoch von unerwunschten Effekten, u. a. auf das autonome Nervensystem begleitet. Um diese Effekte zu messen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d0f8b3852171d7a62315ac65a660b60b
https://doi.org/10.1055/s-0034-1367066

Zobrazit plný text záznamu

Kognitive Defizite in frühen Stadien der schubförmigen multiplen Sklerose

Autor: Irene Daum, M. Tinnefeld, P. M. Faustmann, H. Wilhelm, C. G. Haase

Publikováno v: Aktuelle Neurologie. 35:2-7

INTRODUCTION Awareness of neuropsychological deficits during routine neurological examination appears to be limited in patients with early stage multiple sclerosis. However, cognitive deficits, in particular of memory, attention and visual-spatial ab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5c7610b90ca39485409d8e4f7115819
https://doi.org/10.1055/s-2007-971018

Zobrazit plný text záznamu

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Autor: Dominique de Valeriola, E. Brendel, Martine Piccart, Thierry Gil, M Mano, C. G. Haase, Brian Schwartz, S. Bartholomeus, Dirk Strumberg, Ahmad Awada, Alain Hendlisz

Publikováno v: British Journal of Cancer, 92 (10
British Journal of Cancer

BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour cell proliferation and tumour angiogenesis. This Phase I study was undertaken to determine the safety profile, maximum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbdf7ffc381de061c888c7a31dedc122
https://doi.org/10.1038/sj.bjc.6602584

Zobrazit plný text záznamu

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Autor: Max E. Scheulen, Mitra Tewes, Ralf A. Hilger, D. Voliotis, E. Brendel, Norbert Schleucher, Rudolf Voigtmann, Dirk Strumberg, Brian Schwartz, Markus Faghih, Ahmad Awada, Siegfried Seeber, C. G. Haase, Sonke Korfee, Heike Richly

Publikováno v: Journal of Clinical Oncology. 23:965-972

Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a803f247bc5cc861e64703f2618254
https://doi.org/10.1200/jco.2005.06.124

Zobrazit plný text záznamu

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors

Autor: Dirk Strumberg, N. Schleucher, E. Brendel, U. Sauer, D. Voliotis, Heike Richly, Clemens Unger, Max E. Scheulen, T. Beinert, Siegfried Seeber, Klaus Mross, M. Schweigert, Dirk Behringer, C. G. Haase, M. Tewes, S. Korfee

Publikováno v: Annals of Oncology. 15:1284-1294

Background: The aim of this study was to define the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of the camptothecin glycoconjugate BAY 38-3441, administered as an infusion for 30 min on two separate schedules every

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81098df4ed105969ee85a049b2d033d
https://doi.org/10.1093/annonc/mdh313

Zobrazit plný text záznamu

Idiopathic inflammatory demyelinating diseases of the central nervous system: differentiating between acute disseminated encephalomyelitis and malignant multiple sclerosis

Autor: C. G. Haase, H.-C Diener, P. M. Faustmann

Publikováno v: Journal of Clinical Neuroscience. 6:221-226

Multiple sclerosis (MS) is the most frequent demyelinating disorder of the central nervous system (CNS). However, at presentation, it is frequently difficult to differentiate between malignant MS (MMS) and other fulminant CNS demyelinating diseases l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::710554b3360cb18c22e4e041bbb7a0fe
https://doi.org/10.1016/s0967-5868(99)90507-6

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání